AiMeD, DRISP Join Hands To Promote Medical Device Industry In India And Russia

New Delhi: In a significant move aimed at giving a further boost to robust and long-standing trade relationship between India and Russia, Association of Indian Medical Device Industry (AiMeD) and Centre for the Development of Russia Strategic Partnership (DRISP) have joined hands for taking the medical device industry in two friendly countries to greater heights of growth.

“The Memorandum of Understanding (MoU) signed between DRISP and AiMeD assumes significance as the leaders of India and Russia have outlined their aim of achieving a US $ 30 billion mark in mutual trade by 2025, thus continuing with a dynamic and multifaceted economic engagement, guided by shared interests and a commitment to further deepen bilateral cooperation and our two organisations will contribute in our own humble manner in line with that objective,” said Rajiv Nath, Forum Coordinator, AiMeD.

Nath said that the MoU, inked on October 4, intends to “foster mutual cooperation and understanding for the purpose of promoting the development of business relation between India and Russia, promoting bilateral trade, investment in both the countries and the development and exchange of technology” for the development of medical device industry, which has a seminal role to play in achieving the universal goal of quality and affordable healthcare.

The MoU assumes significance as India is fast emerging as a key supplier of medicines, car and machine parts, textiles and clothing, and food products to Russia. According to St Petersburg International Economic Forum (SPIEF), India-Russia trade hit a record $39.8 billion in 2022–23.

Talking about the MoU, Prasun Prakash, Public Affairs Director, DRISP, said that AiMeD and DRISP Russia would exchange information on economic and commercial matters, that is, trade, investment and technology transfer opportunities as well as trends. “AiMeD will provide free online access to its web based services, except for those sectors, which are priced, for all users,” he said.

Prakash, who signed the MoU on behalf of DRISP, further revealed that AiMeD and DRISP Russia would also extend assistance for visiting healthcare delegations, including officials and businessmen, on both sides, with a view to promoting their business missions and facilitating business collaborations. Nath signed the MoU on behalf of AiMeD.

According to Nath, AiMeD and DRIPS Russia would cooperate in supporting workshops, courses, conferences, and trade fairs organized in both the countries based on sectors and topics of mutual interest, and facilitate networking among the companies of both the countries through their established mechanisms.

Nath said that AiMeD will offer a business-to-business matchmaking bridge role with regard to the promotion of technology and investment tie-ups to companies based in Russia on a cost basis. Similarly, DRISP Russia will assist AiMeD members in their business endeavours. “We will also share enquiries received from its members in Russia and will cooperate with DRISP Russia in referring to the list of manufacturers, suppliers and buyers as required without bias,” said Nath.

It is worth mentioning that it is an umbrella association of Indian manufacturers of medical devices covering all types of medical devices including consumables, disposables, equipment, instruments, electronics, diagnostics and implants. With a primary membership of over 400 manufacturers and additionally of over 200 associate members, AiMeD represents the interest of over 1200 manufacturers of medical devices and helps them address their problems.

Related Posts

  • Pharma
  • December 23, 2024
  • 73 views
Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

  • Pharma
  • December 23, 2024
  • 107 views
NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

India-Latin America trade and collaboration prospects discussed at Kerala University conference

India-Latin America trade and collaboration prospects discussed at Kerala University conference

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt